Karyopharm Therapeutics Inc. - Common Stock (KPTI)
1.9100
+0.00 (0.00%)
NASDAQ· Last Trade: Aug 6th, 4:46 AM EDT
Detailed Quote
Previous Close
1.910
Open
-
Bid
1.900
Ask
1.910
Day's Range
N/A - N/A
52 Week Range
1.800 - 10.99
Volume
2,711
Market Cap
217.76M
PE Ratio (TTM)
-0.1066
EPS (TTM)
-17.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,085,635
Chart
About Karyopharm Therapeutics Inc. - Common Stock (KPTI)
Karyopharm Therapeutics is a biopharmaceutical company focused on developing novel therapies for the treatment of cancer and other serious diseases. The company is dedicated to discovering and commercializing innovative oral medications that target and disrupt the abnormal functioning of cellular pathways involved in disease progression. By leveraging its proprietary SINE (Selective Inhibitor of Nuclear Export) platform, Karyopharm aims to improve patient outcomes through the development of therapies that enhance treatment effectiveness while minimizing toxicity. Their research primarily concentrates on hematological cancers and solid tumors, with a commitment to advancing science and addressing significant unmet medical needs in oncology. Read More
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral nuclear export inhibitor marketed as XPOVIO in multiple myeloma.
Chief Executive Officer Richard Pauls
Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO conference, while also outlining expected regulatory engagement and other development priorities during a re
Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial cancer, while reporting higher first-quarter revenue and reaffirming full-year guidance.
On th
Karyopharm (KPTI) Q3 2025 results show a revenue beat but an earnings miss. The stock rose pre-market as investors focus on XPOVIO sales growth and key Phase 3 data due in 2026.
